$153.540
+5.835 (+3.80%)Al cierre
Noticias de GILD
Eventos de GILD
Applied Intuition Valued at $30B, Plans to Raise Over $1B
The week's largest private market raises came from TypeSafe AI and Oratomic as investors poured money into next generation AI safety systems and fault tolerant quantum hardware.This week's private company news:Autonomous vehicle software startup Applied Intuition has received new investment offers valuing the company at $30B or more, doubling its previous valuation of $15B from June 2025, The Information's Stephanie Palazzolo. The offers are likely to encourage the company to raise at least $1B in the next few months, sources said.Some of the biggest capital raises by private companies this week include:TypeSafe AI– The company announced its Series A funding round led by Andreessen Horowitz, with Sequoia Capital, existing investor DCVC, and several angel investors also participating. The financing values TypeSafe at $7.5B, and Andreessen Horowitz general partner Martin Casado will join its board. Publicly-traded companies operating in the same space include Microsoft, Alphabet, and IBM.Oratomic– The company whose mission is to build the first fault-tolerant quantum computers announced that it has raised a $475M Series B round. Publicly-traded companies operating in the same space include IonQ, Rigetti Computing, and D-Wave Quantum.SignSplit PBC– The fast-growing technology company emerged from stealth with a $400M strategic seed round. The financing commitment, which values SignSplit at $1B, combines capital with a multi-year package of strategic resources to support SignSplit's global rollout. Publicly-traded companies operating in the same space include Cisco, Akamai, and Cloudflare.Vinci– The company announced a $250M Series B co-led by Advent, Temasek and Xora, with participation from AMD Ventures, Eclipse, Khosla Ventures, Madrona and others, valuing the company at $1.5B. Vinci is building an AI-native computational platform designed to fundamentally expand what hardware engineers can create. Publicly-traded companies operating in the same space include Synopsys, Cadence, and Ansys.Atomic Machines– The company announced that it has raised $250M. Publicly-traded companies operating in the same space include Applied Materials, Lam Research, and ASML.Unicorns to watch this week:ReliaQuest– The company remains one of the most prominent private players in AI driven security operations, with its valuation hovering around $3.4B as demand for unified threat detection platforms accelerates. Publicly-traded companies operating in the same space include Okta, Zscaler, and Crowdstrike.MaintainX– The company continues its climb in manufacturing‑tech after recently surpassing the $2.5B valuation mark, riding strong enterprise adoption of its digital maintenance and workflow platform. Publicly-traded companies operating in the same space include Fortive, ServiceNow, and ABM Industries.Enveda Biosciences– The company solidified its unicorn status with a $150M Series D, advancing its machine‑learning platform for discovering therapeutics from natural compounds. Enveda remains one of the most closely watched AI‑native drug‑discovery startups. Publicly-traded companies operating in the same space include Amgen, Bristol-Myers, and Gilead.Underdog Fantasy– Valued around $1.3B, the company continues to scale its sports gaming and pick'em platform amid rising engagement and regulatory expansion across U.S. markets. Publicly-traded companies operating in the same space include DraftKings, Flutter Entertainment, and MGM Resorts.TRM Labs– The blockchain intelligence and analytics platform used by crypto firms and regulators to investigate fraud and financial crime sits near the $1B valuation mark. Publicly-traded companies operating in the same space include Coinbase, Block, and Marathon Digital.IPOs to watch:FireFly Robotics– The company, which designs and manufactures autonomous, all-electric robotic systems for turf and grounds environments, announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public direct listing of its common stock. The company is not selling any shares and will not receive any proceeds in the direct listing.Anthropic– The company is now planning to hold its IPO in November, which is later than the October listing expected by investors, The Wall Street Journal's Corrie Driebusch, Anissa Gardizy, and Kate Clark, citing people familiar with the matter. The report states that a delayed listing would allow the company to share its Q3 results and show its strong competitive position. Anthropic also intends to meet with investors in the coming days, and the meetings are expected to help the company and its bankers gauge investor appetite for the offering, WSJ noted.Nscale Limited– The company has filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Altera Corporation– Altera announced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automation– The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions."Private Markets" is The Fly's recurring series of stories on the latest moves in the private sector, largest unicorn companies and initial public offerings to watch. Fly subscribers, add $PRIVATE to your portfolio for alerts on breaking news in the startup and venture capital space.
Vir Biotechnology Collaborates with Gilead to Develop Novel T-Cell Engagers
Vir Biotechnology (VIR) announced a collaboration and license agreement with Gilead (GILD) to discover and engineer three novel PRO-XTEN dual-masked T-cell engager, TCE, development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs. Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein engineering, its proprietary dAIsY platform for rapid, multiparameter optimization of high-quality TCEs and the universal PRO-XTEN masking technology.
Gilead and Others Notable Gainers in Liquid Options This Morning
Notable gainers among liquid option names this morning include Gilead (GILD) $148.10 +3.88, NetApp (NTAP) $234.28 +5.83, Amgen (AMGN) $412.67 +10.07, Marathon Petroleum (MPC) $443.15 +10.79, and Kroger (KR) $59.70 +1.29.
Cognizant Extends Partnership with Gilead for Five Years
Cognizant (CTSH) announced a five-year extension of its work with Gilead Sciences (GILD). Under the agreement, Cognizant will support Gilead's continued development of DevOps capabilities and the responsible application of agentic AI tools across selected technology programs. Cognizant will apply its life sciences and technology experience to support Gilead's development and operations environment. The work is expected to focus on practical use cases intended to simplify processes, improve delivery and help Gilead's teams execute priority technology programs more efficiently. The agreement follows more than a decade of work in which Cognizant has supported elements of Gilead's global IT infrastructure, platforms, applications and advanced analytics. The updated scope will provide additional support for selected DevOps and AI-enabled capabilities as Gilead continues to strengthen the technology foundations that underpin its business and scientific priorities.
Nurix and Gilead Extend Research Term by Two Years
Nurix Therapeutics (NRIX) announced that Nurix and Gilead (GILD) have agreed to extend the research term for an undisclosed oncology program within the companies' ongoing strategic collaboration by an additional two years. This is the second two-year extension of the research term for this program. Under the collaboration agreement, originally established in 2019, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license drug candidates resulting from the collaboration, and Nurix retains options for 50/50 profit and loss sharing for development, commercialization, and co-detailing on up to two programs in the United States, subject to certain restrictions. For programs in which Nurix exercises its option, the parties will share U.S. development costs as well as profits and losses 50/50, and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments. In connection with this announcement, Nurix will receive a $10M research term extension fee under the amended collaboration agreement. As of May 31, Nurix is eligible to receive up to approximately $1.3B in total payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones. Nurix is also eligible to receive mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products. The first program licensed by Gilead under this agreement, GS-6791, is a potent, selective, oral IRAK4 degrader which is now in Phase 1 clinical development.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.